A ‘designer’ manganese-peptide antioxidant of the world’s toughest bacterium, combined with radiation, have shown to be successful in the development of a vaccine to counter Venezuelan Equine Encephalitis Virus (VEEV), a biothreat agent, and Chikungunya virus, a mosquito-borne illness causing severe outbreaks around the world, according to a study “Deinococcus Mn2+-Peptide Complex: A Novel Approach to Alphavirus Vaccine Development,” published online May 30 in the journal, Vaccine, published by Elsevier, http://www.sciencedirect.com/ science/article/pii/ S0264410X17306242.
Effective vaccines depend upon the human immune system recognizing a biological structure that is similar to that of a disease-causing organism. A manganese-peptide antioxidant complex of Deinococcus, developed by Uniformed Services University of the Health Sciences (USU) pathology professor Dr. Michael J. Daly and his team, has the remarkable property of protecting proteins from ionizing radiation damage but not protecting the genetic material (DNA or RNA) in viruses and bacteria. Using D. radiodurans, listed in the Guinness Book of World Records as “the world’s toughest bacterium” and which can withstand 3,000 times the levels of gamma radiation that human cells can, Daly found that a disease-causing organism (pathogen) can be exposed to gamma radiation in the presence of a Deinococcus Mn complex, and rendered non-replicative (killed) by overwhelming genetic damage, but still maintain the shape of key surface proteins needed to mount a highly protective immune response. This approach was successfully implemented on viruses for the first time by scientists in the USU lab of the late Dr. Radha K. Maheshwari to produce vaccines against VEEV and Chikungunya virus.
This approach offers a simple, rapid, cost effective and potentially universal inactivation strategy that can be applied to any pathogen requiring immediate attention, for example, Ebola and Zika viruses.
“Application of this methodology has the potential to revolutionize all future vaccine development” says Dr. Paridhi Gupta, a scientist in the Maheshwari laboratory, and the study’s co-lead author.
Learn more: New Vaccine Strategy Identified for Explosive Emerging Diseases
[osd_subscribe categories=’vaccines’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “VACCINES’]
The Latest on: Vaccine development
[google_news title=”” keyword=”vaccine development” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Tailored vaccine could one day treat eczema in children
"In combination, these factors make a tailored vaccine a very attractive target as it could limit ... all while also reducing the risk of complications and potentially the development of other atopic ...
- Anixa Inks Joint Development Agreement With Cleveland Clinic To Develop Novel Cancer Vaccines
Biotechnology company Anixa Biosciences, Inc. (ANIX) announced Wednesday that it has entered into a joint development agreement with ...
- Pirbright, The Vaccine Group partner on African swine fever vaccine
The Pirbright Institute is partnering with researchers at The Vaccine Group on a new project that sets out to control African swine fever. Pirbright researchers are collaborating with TVG to ...
- New vaccine 'effective against future coronaviruses that don't even exist yet'
The new vaccine is much simpler in design than other broadly protective vaccines currently in development, which the researchers say should accelerate its route into clinical trials. They believe the ...
- AstraZeneca to withdraw its COVID-19 vaccine globally as demand dips, rare side effects revealed
The pharmaceutical giant AstraZeneca said on Tuesday it is withdrawing its COVID-19 vaccine worldwide due to low demand and following reports that the vaccine caused rare side effects.
via Google News and Bing News